PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-90.13%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
No Data
No Data available this quarter, please select a different quarter.
-148.93%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
-595.65%
Margin decline while TRVN shows 336961.11% expansion. Joel Greenblatt would examine competitive position.
15.04%
Similar R&D growth to TRVN's 15.66%. Walter Schloss would investigate industry innovation requirements.
33.15%
G&A growth while TRVN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.43%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
20.43%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.01%
D&A growth above 1.5x TRVN's 0.47%. Michael Burry would check for excessive investment.
-24.86%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-1164.87%
EBITDA margin decline while TRVN shows 18691.52% growth. Joel Greenblatt would examine position.
-24.41%
Both companies show declining income. Martin Whitman would check industry conditions.
-1160.31%
Operating margin decline while TRVN shows 18425.92% growth. Joel Greenblatt would examine position.
-17.39%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Pre-tax margin decline while TRVN shows 18439.21% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Net margin decline while TRVN shows 18439.21% growth. Joel Greenblatt would examine position.
-23.33%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-23.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.